Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 376

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 376
---
 previously-held shares and acquisition-related costs. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of $ 2,722million .

| F-34 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Acquisition of QRIB Intermediate Holdings, LLC On July 28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of Qunol, a market- leading US-based health & wellness brand. The acquisition strengthened Opella's operations in the Vitamin, Mineral and Supplements (VMS) category. The acquisition of QRIB by Sanofi was completed on September 29, 2023, at a purchase price of $ 1,419million . The final purchase price allocation led to the recognition of goodwill of € 484million , determined as follows:

| (€ million)                                          | Fair value at acquisition date |
| Other intangible assets                              |                            774 |
| Other current and non-current assets and liabilities |                             80 |
| Cash and cash equivalents                            |                              8 |
| Deferred taxes, net                                  |                             -3 |
| Net assets of QRIB Intermediate Holdings, LLC        |                            859 |
| Goodwill                                             |                            484 |
| Purchase price                                       |                          1,343 |

The other acquired intangible assets identified consist of the Qunol brand. Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group. The entire amount of goodwill is deductible for tax purposes over a period of 15years . The imp act of this acquisition is reflected in Net cash provided by/(used in) investing activities of the discontinued Opella business in the consolidated statement of cash flows, and represents a net cash outflow of $ 1,410million . Net assets related to this acquisition, including associated goodwill, are part of Opella's net assets and are therefore reclassified to Assets held for sale and Liabilities related to assets held for sale (see Note D.36.). D.1.3. Significant transactions of 2022 Acquisition of Amunix Pharmaceuticals, Inc. On February 8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals